80 related articles for article (PubMed ID: 3531894)
1. The effect of fibrinogen-methotrexate derivatives on HeLa cell growth.
Dyr JE; Hermanová E; Slavík K; Vodrázka Z
Neoplasma; 1986; 33(4):401-7. PubMed ID: 3531894
[TBL] [Abstract][Full Text] [Related]
2. Organ distribution of fibrinogen-bound methotrexate in mice with Gardner lymphosarcoma.
Slavíková V; Dyr JE; Motycka K; Pristoupilová K; Holý P; Slavík K
Neoplasma; 1987; 34(3):269-76. PubMed ID: 3614463
[TBL] [Abstract][Full Text] [Related]
3. The chemotherapy of C3H mice bearing Gardner lymphosarcoma with bovine fibrinogen-methotrexate derivative.
Motycka K; Slavík K; Dyr JE; Balcarová A; Vodrázka Z
Neoplasma; 1981; 28(1):3-10. PubMed ID: 6895104
[TBL] [Abstract][Full Text] [Related]
4. [Effect of methotrexate (MTX) on neoplastic (HeLa line) and normal (lymphocyte) cells].
Ruano A; Alvarez-Rodríguez Y; Alvarez-Noves J; Valladares Y
Rev Esp Oncol; 1982; 29(4):649-64. PubMed ID: 6927368
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation.
Sahni A; Baker CA; Sporn LA; Francis CW
Thromb Haemost; 2000 May; 83(5):736-41. PubMed ID: 10823272
[TBL] [Abstract][Full Text] [Related]
6. Antileukemic activity of glycated fibrinogen-methotrexate conjugates.
Kanska U; Omar MS; Budzynska R; Nevozhay D; Jagiello M; Opolski A; Boratynski J
Anticancer Res; 2005; 25(3B):2229-34. PubMed ID: 16158968
[TBL] [Abstract][Full Text] [Related]
7. [Effect of rescue treatment with high doses of methotrexate (MTX) followed by leucovorin (LV) on neoplastic cells (HeLa line) and normal sensitized peripheral lymphocytes].
Ruano A; Alvarez-Rodríguez Y; Valladares Y
Rev Esp Oncol; 1982; 29(4):665-73. PubMed ID: 6985426
[TBL] [Abstract][Full Text] [Related]
8. The antileukemic activity of modified fibrinogen-methotrexate conjugate.
Goszczyński T; Nevozhay D; Wietrzyk J; Omar MS; Boratyński J
Biochim Biophys Acta; 2013 Mar; 1830(3):2526-30. PubMed ID: 23168301
[TBL] [Abstract][Full Text] [Related]
9. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. II. Chemotherapy of Gardner lymphosarcoma with pea seed lectin-methotrexate derivative.
Bures L; Motycka K; Bostík J; Slavík K; Jirásek A
Neoplasma; 1986; 33(4):409-16. PubMed ID: 3762803
[TBL] [Abstract][Full Text] [Related]
10. In vitro approach to 7-hydroxymethotrexate interaction on methotrexate metabolism as tool of pharmacokinetic study.
Fabre G; Cano JP; Catalin J; Just S
Int J Clin Pharmacol Res; 1983; 3(6):475-84. PubMed ID: 6590470
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate.
Boratyński J; Opolski A; Wietrzyk J; Górski A; Radzikowski C
Cancer Lett; 2000 Feb; 148(2):189-95. PubMed ID: 10695996
[TBL] [Abstract][Full Text] [Related]
13. Effect of methotrexate on murine bone marrow cells in vitro: evidence of a reversible antiproliferative action.
Strømhaug A; Warren DJ; Slørdal L
Exp Hematol; 1995 May; 23(5):439-43. PubMed ID: 7720815
[TBL] [Abstract][Full Text] [Related]
14. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
Chen J; Gu LJ; Ying DM; Shen M; Wu HJ
Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
[TBL] [Abstract][Full Text] [Related]
15. Degradation of fibrinogen by proteolytic enzymes. I. Characterization and isolation of products and their relation to fibrinolytic states.
Sanchez-Avalos J; Miller SP
Thromb Diath Haemorrh; 1968 Jul; 19(3):499-515. PubMed ID: 4974324
[No Abstract] [Full Text] [Related]
16. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates.
Ofner CM; Pica K; Bowman BJ; Chen CS
Int J Pharm; 2006 Feb; 308(1-2):90-9. PubMed ID: 16361072
[TBL] [Abstract][Full Text] [Related]
17. Degradation products of fibrinogen and crosslinked fibrin-projected clinical applications.
Marder VJ; Budzynski AZ
Thromb Diath Haemorrh; 1974 Sep; 32(1):49-56. PubMed ID: 4616425
[No Abstract] [Full Text] [Related]
18. Chemical binding of folic acid and methotrexate to bovine fibrinogen.
Dyr JE; Slavík K; Vodrázka Z
Thromb Res; 1983 Sep; 31(5):737-46. PubMed ID: 6685928
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate.
Vitols KS; Haag-Zeino B; Baer T; Montejano YD; Huennekens FM
Cancer Res; 1995 Feb; 55(3):478-81. PubMed ID: 7834611
[TBL] [Abstract][Full Text] [Related]
20. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Jolivet J; Chabner BA
J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
